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Epidemiology of primary glomerular diseases in a French region.
Variations according to period and age. Between January 1, 1976 and
December 31, 1990, histological diagnosis of primary glomerular diseases
(PGD) was made in 480 patients born and living at the time of diagnosis
in a region of France, comprising 410,664 inhabitants, of whom 390,574
were aged from 10 to 80 years. The prevalence of PGD during a 70 year
exposure to risk (10 to 80 years of age) was evaluated to 5.7 in 1000 (7.6
in 1000 males and 3.8 in 1000 females). The most common PGD was IgA
nephropathy with a prevalence of 1.9 in 1000 (3.3 in 1000 males, 1 in 1000
females). The annual incidence of the disease was evaluated separately for
three consecutive five-year periods: period A (1976—80), period B (1981—
85), and period C (1986—90). Within each of these three periods the
number of patients with PGD was 179, 170 and 131, respectively, and
annual incidence was 9.3, 8.8 and 6.7 in 100,000. The incidence of IgA
nephropathy remained the same throughout the three periods: 2.6,3.1 and
2.5 in 100,000. The incidence of membranoproliferative glomerulonephri-
tis decreased from 1981 onward (0.9, 0.5 and 0.15 in 100,000), while that
of membranous nephropathy increased slightly (1.2, 1.6 and 1.7 in
100,000). Acute streptococcal glomerulonephritis virtually disappeared
during periods B and C. Lipoid nephrosis was less frequent in period C
and idiopathic proliferative glomerulonephritis with crescents slightly
increased (0.3, 0.4 and 0.6 in 100,000). There was no significant difference
between the three periods regarding the incidence of other PGD. The
incidence of IgA nephropathy was three- to fourfold higher in the adult
aged from 20 to 59 years than in the elderly. In contrast, membranous
nephropathy was threefold more frequent in the elderly than in the adult.
Therefore, only some histopathological forms have a different incidence
according to age, but the major information furnished by this study is that
the risk of occurrence of a POD is similar in the population living in the
area, whatever the age group (10 to 19 years, 6.4 in 100,000 inhabitants; 20
to 39, 7.1 in 100,000; 40 to 59, 8.4 in 100,000; 60 to 79, 8.4 in 100,000). We
also confirm that the most common PGD going to end-stage renal disease
is IgA nephropathy, particularly under 60 years of age (0.8 in 100,000). In
contrast, membranous nephropathy is a less frequent cause of ESRD (0.2
in 100,000).
The prevalence of primary glomerular diseases (PGD) in the
general population is poorly known because optimal conditions
for performing epidemiological surveys are difficult to find. A
great number of PGD are "silent" at onset of the disease and are
diagnosed on urinary tests during routine medical examination. In
a previous study [1] we showed that in 60 percent of adults with
idiopathic IgA nephropathy (IgAN), the disease was discovered
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by chance in employment or military-related routine urinary tests.
Worldwide, IgAN is the most common PGD [2—8] and in our
region the first cause of end-stage renal disease (ESRD) [9].
Variations in the incidence of PGD between periods of time
suggest an influence of environmental factors on the occurrence
of glomerular disease. In the 1980s a decrease in the annual
incidence of membranoproliferative glomerulonephritis (MPGN)
was suggested in retrospective studies [3, 10, 11]. Our prospective
study confirmed these data [4, 12] and indicated that streptococcal
diseases such as acute poststreptococcal glomerulonephritis
(AGN) and acute rheumatic fever were decreasing in parallel with
MPGN [13].
Our prospective study on the epidemiology of POD was started
in 1976. Following our previous preliminary reports at 10 [14] and
at 12 years [4], we can now present results at 15 years. This study
shows the incidence of PGD according to period, age and gender.
It suggests some hypotheses on the role of genetic and environ-
mental factors in the onset of PGD.
Methods
The study was carried out from January 1, 1976, to December 31,
1990, during which time renal biopsy was performed in 942
patients, of whom 480 (5 1%) had PGD. There were twofold more
males (316) than females (164). All patients were born and living
in the study area at the time of diagnosis. The area is located in
western France in the north of Brittany (Cotes d'Armor Depart-
ment) and comprised 410,644 inhabitants, of whom 390,574
were aged from 10 to 80 years. The mean evaluation of inhabitant
number was calculated according to the results of the three last
censuses (INSEE 1975, 1982, 1990) [15]. The distribution of the
population in each age group was as follows: under 10 years of age,
20,070 inhabitants (this group has been excluded from the study); 10
to 19 years, 58,668 inhabitants (males 29,634, females 29,034); 20 to
39 years, 122,969 inhabitants (males 63,471, females 59,478); 40 to 59
years, 108,707 inhabitants (males 54,183, females 54,524); 60 to 79
years, 100,230 inhabitants (males 43,727, females 56,503). This region
of France has a homogeneous and stable population in terms of
migratory behavior (99.3% Caucasians). Only one hospital with a
nephrology department served this population (La Beauchée Hos-
pital, Saint-Brieuc). The Cotes d'Armor region fulfills the criteria of
a standard metropolitan statistical area (SMSA) [16]: (1) a large
population nucleus with a city of at least 50,000 residents (Saint-
Brieuc is a city of 102,966); (2) a total population of at least 100,000
in the area studied (the studied region has 410,644 inhabitants); (3)
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Table 1. Incidence of ESRD and annual rate of renal biopsy according
to the major subdivisions of the area
Major subdivisions (n/105)
St Brieuc Guingamp Lannion Dinan
ESRD 5.2 4.6 4.8 4.6
Renal biopsy 20.4 18.8 19.1 17.8
adjacent communities well integrated with the population of the
major center (Saint-Brieuc is the administrative center for the rural
and fishing population of the area).
To delineate the area of medical influence of our nephrology
department, a method evaluating the performance of renal biopsy
and the incidence of ESRD in each canton of the area was used.
This method was already used in previous reports [1, 4]. When
these values were zero in the cantons farthest from the hospital
during a five year period, we considered that these cantons were
outside the area served by our nephrology department. Verifica-
tion was possible by collaboration with neighboring nephrology
and pathology departments. During the period under study, the
annual rate of renal biopsy was from 16 to 20 new patients for
100,000 inhabitants and incidence of ESRD was from 4.6 to 5.2
new cases for 100,000 inhabitants in the major subdivisions of the
Câtes d'Armor (Table 1).
The diagnostic test for this epidemiological survey was renal
biopsy. Unclassified diagnosis due to inadequate sampling (less
than 7 glomeruli for light microscopy or absence of glomerulus for
immunohistochemisty study) concerned 1.9% of all renal biopsies.
A diagnosis of PGD was considered if there was at the time of
biopsy: (1) no report of any known associated systemic disease
(systemic lupus erythematosus, polyarteritis nodosa, Wegener's
granulomatosis, Goodpasture syndrome, Henoch-Schönlein dis-
ease, lymphoma, carcinoma, Alport syndrome); (2) negative se-
rology for hepatitis B and anti-nuclear factor. During the study
period serology for anti-neutrophil cytoplasmic antibody was not
collected; (3) no report of familial hematuria. Renal biopsy
specimens were processed and stained for light microscopy and
immunohistochemisty using polyclonal antisera against human
IgG, 1gM, IgA, C3, Clq, kappa, and lambda light chains. Electron
microscopy was not systematically performed.
To evaluate the evolution of the incidence of PGD according to
period and age, we distinguished three consecutive five-year
periods (period A 1976—80; period B 1981—85; and period C
1986—90) and four age groups (10 to 19 years; 20 to 39 years, 40
to 59 years, and 60 to 79 years). Mean age (SD) at the time of renal
biopsy increased slightly over the three periods [A, 47 (14); B, 50
(14); C, 52 (14) years], as did the sex ratio (males/females: 1.3, 1.5
and 1.6, respectively). Clinical indications for renal biopsy (Table
2) were recent onset uremia (acute uremia if onset was less than
2 months and chronic uremia if onset was more than 2 months),
nephrotic syndrome, persisting proteinuria and hematuria, per-
sisting idiopathic proteinuria or chronic hematuria. Annual rate of
renal biopsy was not significantly different during the three
periods: 18.7, 20.1 and 16.2 patients for 100,000 inhabitants for
periods A, B and C, respectively. More than 80% of renal biopsies
were performed by the same physician (PS) and all renal biopsy
specimens were examined by the same pathologist (MPR).
We cannot prove that all patients having an indication of renal
biopsy and living in the area were sent to our nephrology
department. However, the leakage was probably low, since only 11
out of the 942 biopsied patients studied had undergone renal
biopsy in another nephrology department in Brittany during the
15 year period. Clinical information about the evolution of PGD
in these 11 patients was taken into account for the calculation of
incidence of ESRD. Conditions for a prospective epidemiological
study were maximized by close collaboration with practitioners,
urologists and employment physicians in the area. In 1984 [1] we
reported that more than 65% of patients with IgAN had been sent
to a urologist before an outpatient visit in our nephrology
department, no doubt since hematuria leads the practitioner to
address the patient to a urologist for cystoscopy. The five urolo-
gists working in the area were closely associated to this study
(Acknowledgments). As most cases of PGD are "silent" at onset,
the role of routine screening by school, employment and army
physicians is essential [1], and we were able to collaborate with the
major medical screening institutions in the area.
Annual incidences of PGD and of each histological form in
each age group of the general population at the time of renal
biopsy and at the time of ESRD were studied. The annual
incidence was calculated as follows:
Annual incidence
Total number of new patients for the period under study
Population in age group/duration of the period (years)
Prevalence was evaluated only when annual incidence was
stable according to periods. It was calculated as follows:
Prevalence = Annual incidence X time of exposure to risk (years)
Results of incidence are given as number per 100,000 inhabit-
ants and those of prevalence as number per 1,000 inhabitants.
Among 348 patients who started dialysis during the period
under study, 99 (28.4%) had PGD and 81 of 99 had had a renal
biopsy at the time of diagnosis of the renal disease. However, only
the 75 patients who underwent renal biopsy after January 1, 1976
were to be considered in determining the incidence of PGD at the
time of ESRD. More than 85% of these patients who started renal
replacement therapy with the diagnosis of PGD after January 1,
1981 had had a histological diagnosis of renal disease during the
first period (A). Therefore, the annual incidence of ESRD due to
PGD has been evaluated for the last decade (periods B and C) of
the study. The risk of the evolution to ESRD due to PGD was
calculated as follows:
Percentage of patients at risk of ESRD (%)
—
Incidence at the time of renal biopsy (n/105) (period A)
Incidenceat the time of ESRD (n/iC)5) (periods B and C)
By means of chi-squared analysis we compared the different
clinical presentations and the annual incidences of POD and of
each histological form according to period and age.
Results
General data on the incidence of PGD
The annual incidence of POD in the area was 8.2 per 100,000
inhabitants. It was significantly decreased in period C compared
to period A (Table 3). The incidence of ESRD due to PGD was
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Table 2. Indications of renal biopsy: Evolution of annual rate according to period
Period A
(1976—80)
Period B
(1981—85)
Period C
(1986 —90) 1976—90
N (%) I N (%) IN (%) IN (%) I
ARF
CRF
NS
P + H
P
H
52
50
70
91
33
24
(16.5)
(15.5)
(21.8)
(28.5)
(10.5)
(7.)
3.2
3.0
3.6
5.5
2.0
1.4
83
69
71
80
25
15
(24.2)
(20.2)
(20.7)
(23.3)
(7.3)
(4.3)
5.0
4.2
3.7
4.8
1.5
0.9
52
48
78
58
23
20
(18.6)
(17.2)
(28.0)
(20.7)
(8.3)
(7.2)
3.2
2.9
4.0
3.5
1.4
1.2
187
167
219
229
81
59
(19.8)
(17.7)
(23.2)
(24.3)
(8.6)
(6.2)
3.8
3.4
3.8
4.6
1.6
1.2
Total 320 (100) 18.7 343 (100) 20.1 279 (100) 16,2 942 (100) 18.4
Abbreviations are: ARF, acute renal failure; CRF, chronic renal failure; NS, nephrotic syndrome; P. chronic proteinuria; H, chronic hematuria; I,
annual rate (n/tO5).
Table 3. Primary glomerular disease diagnosed by renal biopsy for a 15 year period comprising 3 consecutive five year periods
Period A Period B Period C Total
(1976—80)
Type of glomerular disease N (%) I
(1981—85) (1986—90) (1976—90)
N (%) I N (%) I N (%) I
Nephrosis 24 (13.4) 1.2 17 (10.0) 0.9 14 (10.7) 0.7 55 (11.4) 0.95
FSG 22 (12.3) 1.2 21 (12.3) 1.1 8 (6.1) 0.4 51 (10.6) 0.80
MN 22 (12.3) 1.2 30 (17.6) 1.6 33 (25.2) 1.7 85 (17.7) 1.40
IgAN 52 (29.2) 2.6 61 (35.8) 3.1 48 (36.6) 2.5 161 (33.4) 2.70
MPGN 19 (10.6) 0.9 10 (5.9) 0.5 3 (2.3) 0.15 32 (6.6) 0.55
Poststrept AGN 22 (12.3) 1.2 8 (4.7) 0.4 3 (2.3) 0.15 33 (6.8) 0.55
Mes prolif GN 9 (5.0) 03 10 (5.8) 0.5 9 (6.8) 0.5 28 (5.8) 0.45
Crescentic prolif GN 6 (3.3) 0.3 8 (4.7) 0.4 11 (8.5) 0.6 25 (5.2) 0.60
Foc seg prolif GN 3 (1.6) 0.2 5 (2.9) 0.3 2 (1.5) 0.1 10 (2.0) 0.20
Primary glomerular disease 179 (100) 9.3 170 (100) 8.8 131 (100) 6.7a 480 (100) 8.2
X2 = 6.9 p < .02with period A
Abbreviations are: nephrosis, idiopathic nephrotic syndrome with minimal change or focal segmental glomerular sclerosis; FSG, focal segmental
glomerular sclerosis (without nephrotic syndrome); MN, membranous nephropathy; IgAN, IgA nephropathy (Bergers' disease); MPGN, membrano-
proliferative glomerulonephritis type I; Poststrept AGN, poststreptococcal acute glomerulonephritis; Mes prolif GN, mesangial proliferative
glomerulonephritis; Crescentic prolif GN, idiopathic crescentic proliferative glomerulonephritis; Foc seg prolif GN, focal segmental proliferative
glomerulonephritis (excluding idiopathic IgA nephropathy and Henoch Schonlein disease).
Table 4. Histological forms of primary glomerular disease according to period: Incidence at the time of ESRD
Period A Period B Period C
(1976—80)
Histological forms of PGD N (%) I
(1981— 85) (1986 —90) 198 1—90
N (%) I N (%) I N (%) I
Nephrosis — — — 1 (2.3) 0.05 1 (3.2) 0.05 2 (2.6) 0.05
FSG 2 (8.3) 0.1 10 (22.7) 0.6 3 (9.7) 0.15 13 (17.4) 0.35
MN 2 (8.3) 0.1 2 (4.6) 0.1 5 (16.1) 0.3 7 (9.3) 0.18
IgAN 5 (20.9) 0.3 17 (38.6) 0.9 11 (35.5) 0.6 28 (37.3) 0.80
MPGN 2 (8.3) 0.1 1 (2.3) 0,05 3 (9.7) 0.15 4 (5.3) 0.10
Crescentic prolif GN 2 (8.3) 0.1 6 (13.6) 0.35 3 (9.7) 0.15 9 (12.0) 0.23
Other 1 (4.2) 0.05 3 (6.8) 0.15 1 (3.2) 0.05 4 (5.3) 0.10
Unclassified 10 (41.7) 0.6 4 (9.1) 0.2 4 (12.9) 0.20 8 (10.8) 0.20
Primary glomerular disease 24 (100) 1.35 44 (100) 2.4 31 (100) 1.65 75 (100) 2.01
evaluated to 2 per 100,000 inhabitants (Table 4). Thus, 21.5% of incidence of POD in all age groups made it possible to evaluate
patients with PGD were at risk to reach ESRD after at least ten the prevalence of POD in the general population living in the area
years of evolution of PGD (Table 5). Idiopathic IgA N was the to 5.7 per 1,000 inhabitants and according to gender to 7.6 per
most frequent PGD going to ESRD (0.8 per 100,000 inhabitants) 1,000 males and 3.8 per 1,000 females. The risk of going to ESRD
in our area. The incidence of POD in each age group was similar due to PGD peaked in the 40 to 59 year age group (2.8 per
(Table 6). A predominance of males was found in each age group 100,000) and decreased after 60 years (2.0 per 100,000). Risk of
(incidence in general, male and female populations): 10 to 19 evolution to ESRD was fourfold higher in males than in females
years, 6.4, 8.3 and 4.4 per 100,000; 20 to 39 years, 7.1, 9.1 and 4.8 (3.23 vs. 0.86 per 100,000; Table 7). It was the highest in males
per 100,000; 40 to 59 years, 8.4, 11.0 and 5.5 per 100,000; and 60 with IgAN and those with crescentic proliferative glomerulone-
to 79 years, 8.4, 11.0 and 5.8 per 100,000 inhabitants. The similar phritis (CGN; Table 5).
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Table 5. Percentage of patients at risk of ESRD during period 1981—90
Percentage ofpatients
Histological forms of PGD
%
AllMales Females
Nephrosis 7 — 4.2
FSG 62 37 29.2
MN 22 8 15
IgAN 54 12 30.7
MPGN 20 — 11.2
Poststrepto GN — — —
Crescentic prolif GN 85 20 76
Other and unclassified 16 8 14.3
Primary glomerular disease 35 18 21.5
Evolution of annual incidence of various histological forms of
PGD according to period and age
We studied six histological forms of PGD in particular: IgAN,
membranous nephropathy (MN), MPGN, poststreptococcal AGN,
nephrosis with minimal change or focal segmental glomerular scle-
rosis (nephrosis), and CGN (excluding crescentic IgAN).
(1.) Idiopathic IgA nephropathy. IgAN was the most common
PGD, with a frequency of 33.4% in biopsied patients. Its annual
incidence in the general population over 10 years of age was 2.7
per 100,000 and remained unchanged during the 15 year period
(Table 3). Prevalence of IgAN in the general population was 1.9
per 1,000 inhabitants, 3.3 per 1,000 males and 1 per 1,000 females.
Mean age (SD) at the time of diagnosis by renal biopsy was 38 (15)
years. Peak of incidence of diagnosis was between 20 and 40 years
of age. Threefold more males than females had IgAN whatever
the period and the age group (Table 6). However, the sex ratio
(males to females) was the highest between 10 and 19 years of age.
IgAN was detected in 60 percent of the patients by routine urinary
tests at school, work and military medical visits. Two out of three
patients with IgAN had undergone cystoscopy. Incidence of
ESRD due to IgAN was the highest in the 40 to 59 year age group
(Table 7). It was at least sevenfold higher in males than in females
(1.5 vs. 0.2 per 100,000). Thus, 30.7% of patients with IgAN were
at risk to reach ESRD after at least ten years of evolution of the
disease. The risk was higher in males (1 out of 2) than in females
(1 out of 8). No case of ESRD due to IgAN in patients less than
25 years of age was observed in the area during the period under
study.
(2.) Membranous nephropathy. Idiopathic MN was the second
most frequent PGD with a frequency in biopsied patients of
17.7% (Table 3). Its annual incidence increased from period A
(1.2 per 100,000) to periods B and C (1.6 and 1.7 per 100,000
inhabitants) (P < 0.05 between periods A and C). Peak of
incidence of diagnosis according to age group occurred between
60 and 80 years (Table 6). Prevalence of males was low and sex
ratio males to females was 1.2. In at least 80% of patients,
diagnosis of MN was made at onset of a nephrotic syndrome. MN
was an infrequent cause of ESRD (0.18 per 100,000) but its
incidence was threefold higher in males than in females (0.3 vs. 0.1
per 100,000). The risk of such an evolution involved 1 out of 5
males and only 1 out of 12 females. Thus, 15% of patients with
MN were at risk to reach ESRD after at least ten years of
evolution of the disease (Table 5).
(3.) Membranoproliferative GN and poststreptococcal AGN.
MPGN was diagnosed in 6.6% of biopsied patients with PGD.
The annual incidence decreased from the beginning of the study.
During the first period, it was 0.9 per 100,000 inhabitants and
sharply dropped during the two following periods (0.5 and 0.15
per 100,000 for periods B and C, respectively; P < 0.02 between
periods A and C). Simultaneously, we observed a progressive
decrease in the incidence of poststreptococcal AGN: 1.2, 0.4 and
0.15 per 100,000 for periods A, B and C, respectively. An update
of a survey on the frequency of outpatient visits to cardiologists
for complications of acute rheumatic fever showed a concomitant
decrease in such visits: 1.3, 0.3 and 0.1 per 100,000 for periods A,
B and C, respectively (P < 0.01 between periods A and C). The
annual incidence according to gender was similar in patients with
MPGN and those with poststreptococcal AGN (0.9 and 0.3 per
100,000 for males and females, respectively), with a threefold
higher incidence in males than in females. Both glomerular
diseases had two peaks of incidence of diagnosis according to age
groups (10 to 19 and 40 to 79 years, respectively). Prevalence of
males was found in all periods and age groups. About 11.2% of
patients with MPGN were at risk to reach ESRD after at least ten
years of evolution of the disease, and the frequency of ESRD due
to MPGN was 5.3% of patients with PGD. No case of ESRD that
could be due to poststreptococcal AGN of which the diagnosis
was made in period A was observed during the last decade of the
study.
(4.) Crescentic proliferative glomerulonephritis. CGN was diag-
nosed in 5.2% of biopsied patients with PGD. The annual
incidence was 0.6 per 100,000 inhabitants. It was slightly increased
in period C (0.6 per 100,000) compared to period A (0.3 per
100,000) and was diagnosed more often over 60 years of age (1.7
per 100,000) than under 60 years (0.4 per 100,000, P <0.02). The
incidence was twofold higher in the 60 to 79 year age group than
in the 40 to 59 year age group (0.8 per 100,000) and eightfold
higher than in the 20 to 39 year age group (0.15 per 100,000, P <
0.01). The sex ratio was from 1.8 to 2. In 8 out of 10 patients,
diagnosis of CGN was suggested because renal failure with
glomerular signs (hypertension, proteinuria and hematuria) was
rapidly progressive. ESRD due to CGN was eight times higher in
males than in females (0.4 vs. 0.05 per 100,000), and male
prevalence was the highest between 60 and 80 years of age (0.9 per
100,000 males vs. 0.1 per 100,000 females, P < 0.02). Thus, 76%
of patients with CGN were at risk to reach ESRD after at least ten
years of evolution of the disease and the risk existed in about two
out of three males and in one out of five females with CGN.
(5.) Nephrosis. Frequency of nephrosis was 11.4 percent of
biopsied patients with PGD. The annual incidence was 0.9 per
100,000 inhabitants. It regularly decreased during the 15 year
period: 1.2, 0.9 and 0.7 per 100,000 for periods A, B and C,
respectively. Nephrosis was diagnosed more often in females than
in males (sex ratio males to females, 0.6). Peak of incidence of
diagnosis occurred between 10 and 20 years of age (1.5 per
100,000) and was 0.6 to 1 per 100,000 in other age groups.
Incidence of ESRD due to nephrosis was rare in our area (0.05
per 100,000), with only 5.5% of patients with nephrosis at risk to
reach ESRD after at least ten years of evolution.
Discussion
This work reports on a 15 year prospective epidemiological
study of PGD that started in January 1976 in the area of
Saint-Brieuc. Our results confirm those published after 10 and 12
years of the study [1, 4, 9, 12, 13, 17] and bring new data. We
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Table 6. Annual incidence at biopsy of some histological types of primary glomerular disease according to age and gender
.
Histological type of
primary glomerular disease
Age groups years
no. of patients
M
10—19
F all M
20—39
F all M
40—59
F all M
60—79
F all
Total
M F all
IgAN 4.0 0.5 2.3 5.8 2.4 4.2 5.4 1.7 3.9 1.5 0.4 1.1 4.8 1.4 2.7
MN 1.1 0.7 0.9 0.9 0.7 0.8 1.3 1.2 1.2 3.2 2.4 2.8 1.9 1.6 1.4
Crescentic prolif ON — — — 0.3 — 0.2 1.0 0.6 0.8 2.3 1.3 1.7 0.9 0.5 0.6
Nephrosis 0.9 2.1 1.5 0.8 1.2 1.0 0.7 0.6 0.6 0.5 1.0 0.8 0.7 1.1 0.95
MPON 0.7 0.5 0.6 0.3 0.2 0.2 1.6 0.5 1.0 1.0 0.2 0.6 0.9 0.3 0.55
Poststrept AGN 1.3 0.5 0.9 0.6 0.2 0.4 0.3 0.4 0.3 1.5 0.2 0.7 0.9 0.3 0.55
Other and unclassified 0.3 0.1 0.2 0.4 0.1 0.3 0.7 0.5 0.6 1.0 0.3 0.7 0.8 0.3 1.45
Primary glomerular disease 8.3 4.4 6.4 9.1 4.8 7.1 11.0 5.5 8.4 11.0 5.8 8.4 10.9 5.5 8.2
Table 7. Annual incidence at ESRD of some histological types of primary glomerular disease according to age and gender (1981—90)
Histological type of
Age groups years
I of patients10—19 20—39 40—59 60—79 Tota
primary glomerular disease M F all M F all M F all M F all M F all
IgAN — — — 0.9 0.15 0.6 2.9 0.2 1.6 0.9 0.3 0.4 1.5 0.2 0.80
MN — — — — — — 0.4 0.2 0.3 0.7 0.2 0.4 0.3 0.1 0.18
Crescentic prolif ON — — — 0.3 — 0.2 0.1 — 0.1 1.1 0.2 0.6 0.4 0.05 0.23
Nephrosis — — — 0.15 — 0.08 — — — — 0.17 0.1 0.05 0.05 0.05
MPGN — 0.3 0.17 0.15 — 0.08 0.4 — 0.2 0.2 — 0.1 0.18 0.06 0.10
PostreptAGN — — — — — — '
Other and unclassified — — — — — — 0.9 0.4 0.6 0.6 0.5 0.4 0.8 0.3 0.65
Primary glomerular disease — 0.3 0.17 1.5 0.15 1.0 4.7 0.8 2.8 3.5 1.37 2.0 3.23 0.86 2.01
confirm that IgAN is the most common POD, not only among the
patients biopsied for POD [21 but also in the general population
of the area, Additionally, in this area IgAN is the most frequent
POD in the adult, while MN is the most frequent POD in the
elderly [18].
We also confirm that the decline in MPON, poststreptococcal
AON and acute rheumatic fever was closely associated in this area
[13]. The decline in the incidence of streptococcal diseases in
developed countries has been accompanied by a comparable
decrease in the incidence of nonsuppurative complications of
streptococcal infection such as acute rheumatic fever and acute
glomerulonephritis [19, 20]. This evolution suggest the role of
streptococcal infection in the onset of MPON [13, 21]. The
decline in these streptococcal diseases [6, 7, 9—11, 20—22] is
commonly attributed to an improved standard of living, better
public health and the generalized early treatment of pharyngeal
infections. The role of antibiotics in preventing these diseases is
questionable, since the decline began prior to the introduction of
antibiotics [19]. However, it seems likely that antibiotics are
responsible for some acceleration in the rate of decline [11, 13,
19]. Therefore the progressive disappearance of these two forms
of POD can explain the decrease in the incidence of POD during
the last period (C) of our study. The incidences of the various
forms of POD that we found are similar to those recently
published in France [3, 6, 8] and in the Netherlands [5]. It is also
interesting to point out the similarity in frequencies of histological
forms of POD in the 480 biopsied patients with those reported in
the USA [23], the United Kingdom [24] and Taiwan [22].
The major information furnished by this epidemiological study
is that the risk of occurrence of a POD is similar in the population
living in our region, whatever the age group. Only some his-
topathological forms have a different incidence according to age.
Therefore, it is possible to evaluate the prevalence of POD in the
general population to 5.4 per 1,000 inhabitants, this value being
the same as was speculated in 1988 [4] and higher than that
evaluated in 1984 on the basis of the literature [25]. The preva-
lence of POD in the male population (7.6 per 1,000) is twofold
that in the female population (3.8 per 1,000). However, this
predominance was not similar in different forms of POD. The
prevalence of IgAN in the general population is 1.9 per 1,000
inhabitants and according to gender is 3.3 per 1,000 males and 1
per 1,000 females. In contrast, prevalence of MN in the general
population is 1.2 per 1,000 inhabitants and is as frequent in males
(1.4 per 1,000) as in females (1.3 per 1,000). Today two out of
three patients with PUN have either IgAN or MN. The prevalence
of nephrosis in the general population is evaluated to 0.6 per 1,000
inhabitants. This glomerular disease is more frequent in the
female (0.8 per 1,000) than in the male population (0.5 per 1,000).
Therefore the frequency of nephrosis in the adult would be
threefold [26] to sevenfold [27] lower than in a child under 15
years of age. Males would be more prevalent in childhood
nephrosis [26] and females more prevalent in adult nephrosis [28].
Longitudinal study brings new data on the evolution of some
histological types of POD according to period and age. We
confirmed the progressive decrease in the incidence of MPON
and poststreptococcal AON in our area during the 15 year period,
but we observed that this decrease was fundamentally in the
youngest age group while these two forms of POD still existed in
the elderly [18, 29]. The incidence of IgAN remained similar
throughout the period under study while that of MN was slightly
increasing. Such a progressive increase during the last decade has
also been suggested in other recent studies [3, 6, 30], and could be
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interpreted as the consequence of the increase in average lifetime
and also the possible role of some environmental factors such as
drugs [31] or solvents [32]. The incidence of IgAN is three- to
fourfold higher in the adult aged from 20 to 59 years than in the
elderly. In contrast, MN is threefold more frequent in the elderly
than the adult [18, 29]. Immunogenetic susceptibility to develop-
ing MN is known [33, 34] and is confirmed in our Caucasoid
population with a significant association between class II allele
HLA-DR3 and the disease [35]. Similarly, genetic factors could be
implicated in the prognosis of IgAN, as recently reviewed [36].
The stability of the annual incidence of IgAN during our 15 year
prospective study suggests that immunogenetic factors could be
more important than environmental factors in the onset of IgAN.
Moreover, we have recently shown a significant association be-
tween a familial history of arterial hypertension and the presence
of arterial hypertension at the time of renal biopsy in IgAN
patients [37]. In our area, class II allele DR4 is in linkage
disequilibrium with B12 [44] in IgAN patients with familial
arterial hypertension and in those who progress to ESRD [35, 37].
Therefore, HLA alleles in IgAN could be markers of the severity
of the disease [38]. In adult nephrosis we found a convincing
association with DR7 [28, 35], suggesting, as in the child [26],
an immunogenetic susceptibility to developing this glomerular
disease.
The incidence of ESRD due to PGD decreased by about 30%
during the last five year period and is mainly due to the significant
decrease in the incidence of MPGN, which was an important
cause of ESRD [10, 11, 21]. Today, in our area MPGN has
become a rare cause of ESRD, accounting for only 5% of
glomerular causes of ESRD during the last decade. Such a
decrease of incidence of ESRD due to PGD was confirmed in
Western Europe [39] and in the USA [40]. Our study confirms the
good renal prognosis of poststreptococcal AGN.
In our area, the average incidence of ESRD due to POD was 2
per 100,000 inhabitants during the last decade, and about 21.5%
of patients with PGD may develop ESRD. However, our study
shows variations according to age and gender. ESRD due to PGD
is more frequent in the 40 to 59 year age group (2.8 per 100,000)
than in other age groups (ito 2.0 per 100,000). The prevalence of
males is found in every age group, confirming the recent data of
the EDTA [39]. The risk of developing ESRD due to PGD is six-
to eightfold higher in males than in females in the 20 to 59 year
age group and two- to threefold only over 60 years. Thus, male
gender is a risk factor for worse renal prognosis of PGD,
particularly under 60 years, as already suggested with other
nephropathies [41].
We confirm that IgAN is the leading cause of ESRD due to
POD in our area, representing 40% of PGD reaching ESRD
during the last decade, as was already evaluated in 1988 [9, 17].
Such information cannot yet be obtained from the registry of the
EDTA since only 40% of new patients accepted for renal replace-
ment therapy in 1985 had POD confirmed by histological exami-
nation. Histological diagnosis at ESRD varied among countries,
ranging from less than 10 to nearly 90% with 42% in France [42].
In our area during the last decade more than 85% of patients who
started renal replacement therapy with the diagnosis of PGD had
had a histological diagnosis of renal disease during the first study
period. A recent study carried out in another French region
confirms our results [8]. About 30% of patients with IgAN are at
risk to reach ESRD after at least ten years of evolution of the
disease, confirming the evaluations made in several studies [2, 38].
Thus we can consider that about 400 new patients with IgAN go
into renal remplacement therapy every year in France. This
number is higher than that of a first evaluation made in 1987 [43].
The risk of such a poor renal prognosis is the highest between 40
and 59 years of age, where IgAN represents more than 60% of
glomerular causes of ESRD in males and 40% in females. Over 60
years of age, IgAN still represents 25% of glomerular causes of
ESRD in males, its frequency being equivalent to that of MN
(20%) and CGN (25%). The greater frequency of arterial hyper-
tension in the male population [44, 45] and increased genetic risk
of hypertension [24, 37] could contribute to the progression to
ESRD of patients with PGD, particularly in those with IgAN [37].
An interesting recent experimental study has examined the pos-
sibility of a Y-linked effect on blood pressure operating through
the kidney [46]. In our area, MN is not a frequent cause of ESRD
and only 15% of patients may reach ESRD ten years after the
diagnosis of the disease. These results conflict with those of
Ponticelli et a! [47], but are in agreement with other studies in
France [48] and in Italy [49]. It is interesting to point out the
increasing incidence of diagnosis of MN, which seems to be
associated with an increasing incidence of ESRD due to MN
(during the last 5 year period of the study). A prevalence of
females characterizes nephrosis, and this could explain a more
benign renal prognosis of this glomerular disease. CGN is another
PGD which essentially occurs after 60 years of age and where two
out of three patients reaches ESRD. However, the risk of worse
renal prognosis is nine- to tenfold higher in males than in females.
In conclusion, our study is the first to give epidemiological
information on the similar frequency of PGD in every age group
of a general population. It demonstrates that the two major
chronic PGD are now IgAN and MN and that the IgAN is the first
glomerular cause of ESRD in adults aged under 60 years,
accounting for the prevalence of males among patients with
ESRD due to PGD.
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